|
|
Volumn 14, Issue 3, 2015, Pages 161-162
|
|
What does it take to produce a breakthrough drug?
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ASUNAPREVIR;
BOCEPREVIR;
CEFTAROLINE;
CEFTOBIPROLE;
DACLATASVIR;
DALBAVANCIN;
DAPTOMYCIN;
DASABUVIR;
DONEPEZIL;
GALANTAMINE;
INTERFERON;
LEDIPASVIR;
LINEZOLID;
MEMANTINE;
OMBITASVIR;
ORITAVANCIN;
PARITAPREVIR;
PEGINTERFERON ALPHA2A;
PEGINTERFERON ALPHA2B;
RIBAVIRIN;
RITONAVIR;
RIVASTIGMINE;
SIMEPREVIR;
SOFOSBUVIR;
TEDIZOLID;
TELAPREVIR;
TELAVANCIN;
TIGECYCLINE;
ANTIVIRUS AGENT;
ALZHEIMER DISEASE;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG RESEARCH;
HEPATITIS C VIRUS;
HUMAN;
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;
METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION;
NONHUMAN;
PREVALENCE;
PRIORITY JOURNAL;
PUBLIC HEALTH;
SHORT SURVEY;
HEPATITIS C;
PHARMACOLOGY;
STAPHYLOCOCCAL INFECTIONS;
TRENDS;
ALZHEIMER DISEASE;
ANTIVIRAL AGENTS;
DRUG APPROVAL;
DRUG INDUSTRY;
HEPATITIS C;
HUMANS;
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;
PHARMACOLOGY;
STAPHYLOCOCCAL INFECTIONS;
|
|
EID: 84924076465
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4570 Document Type: Short Survey |
|
Times cited : (61)
|
|
References (3)
|
